Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 41 min ago
PreprintCC BY-NC-ND 4.0HAL

Differential Effects of Distinct Type I Interferons and IFN Inducers on Fc Receptor landscape and myeloid cell function

Abstract

Antiviral monoclonal antibodies (mAbs) rely on Fc-mediated effector functions, which depend on interactions with Fc receptors (FcRs) expressed on immune cells such as monocytes and dendritic cells (DCs). While combinations of antiviral mAbs with type I interferons (IFN-I) or IFN inducers are being explored to enhance therapeutic efficacy, the impact of these immunomodulators on FcR expression remains poorly understood. In this study, we investigated the effects of IFN-α2, IFN-β, and the IFN-inducer TAK-981 (a SUMOylation inhibitor) on FcR modulation and functional activation in human monocyte subsets and monocyte-derived DCs (moDCs). Using flow cytometry and imaging techniques, we mapped the expression of activating FcγRs (CD64, CD32A, CD16A) and neonatal FcR (FcRn) under steady-state and stimulated conditions. We found that IFN-I selectively downregulates CD16A expression in classical monocytes while preserving other FcRs, whereas TAK-981 reduces FcRn expression in classical monocytes without affecting CD16A. Additionally, IFN-β and TAK-981 but not IFN-α2, selectively enhanced FcγRI expression in moDC. IFN-β also induced a stronger maturation and functional activation program in monocytes and moDCs compared with IFN-α2, whereas TAK-981 largely reproduced the IFN-β-driven phenotype and secretory profile. Furthermore, we demonstrated that IFN-I signaling alters the spatial distribution of FcRs, with IFN-β and TAK-981 promoting distinct redistribution patterns of FcγRs in monocytes and moDCs. These findings reveal a novel layer of FcR regulation, highlighting that IFN-I and IFN inducers differentially modulate FcR expression, localization, and functional activation in a cell-type- and stimulus-specific manner. Overall, this work provides a framework for understanding how IFN-I-based immunotherapies may influence Fc-mediated immune functions while preserving FcRn-dependent antibody persistence.

Related

  1. AXIN1 and AXIN2 regulate the WNT-signaling landscape to promote distinct mesoderm programs
    Rocío Hernández-Martínez, Sonja Nowotschin, Luke T. G. Harland +6
    Developmental CellPeer-reviewedCC BY8 citedMolecular biology & gene regulationOpenAlex
  2. Vasopressin V2 receptor phosphopeptide reshapes the conformational landscape of arrestin-2 beyond C-tail detachment
    M. Bzowka, R. Feser, S. Aureli +2
    bioRxivPreprintCC BY-NDFull textGeneral biochemistrybioRxiv
  3. Anisomycin-induced ribosome collisions follow a dose-dependent positional rule, distinct from the UV-induced collision landscape
    S. Chamois, J. Soudet, V. Ricci +3
    bioRxivPreprintCC BYFull textMolecular biology & gene regulationbioRxiv
  4. Energy Landscape Sampling Reveals Ligand-Dependent Structural Dynamics of the Protease-Activated Receptor 1.
    Inken Kaja Schwerin, Shihai Jiang, Claudia Stäubert +2
    Journal of chemical information and modelingPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  5. Type I and III interferons differentially encode inflammatory gene activation through threshold control of ISGF3 dynamics
    H. Dubon Martinez, R. Chettiyar, M. McAuley +1
    bioRxivPreprintAll rights reservedFull textMolecular biology & gene regulationbioRxiv
BibTeX
@misc{bru2026differential,
  title = {{Differential Effects of Distinct Type I Interferons and IFN Inducers on Fc Receptor landscape and myeloid cell function}},
  author = {Rémi Bru and Océane Paris and Guillaume Bossis and Stephanie Boireau and Mar Naranjo-Gomez and Mireia Pelegrin},
  howpublished = {HAL},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.01.756027},
  url = {https://hal.science/hal-05841901v1},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - UNPB
TI  - Differential Effects of Distinct Type I Interferons and IFN Inducers on Fc Receptor landscape and myeloid cell function
AU  - Rémi Bru
AU  - Océane Paris
AU  - Guillaume Bossis
AU  - Stephanie Boireau
AU  - Mar Naranjo-Gomez
AU  - Mireia Pelegrin
PY  - 2026
DA  - 2026/10/01
PB  - HAL
DO  - 10.64898/2026.10.01.756027
UR  - https://hal.science/hal-05841901v1
AB  - Antiviral monoclonal antibodies (mAbs) rely on Fc-mediated effector functions, which depend on interactions with Fc receptors (FcRs) expressed on immune cells such as monocytes and dendritic cells (DCs). While combinations of antiviral mAbs with type I interferons (IFN-I) or IFN inducers are being explored to enhance therapeutic efficacy, the impact of these immunomodulators on FcR expression remains poorly understood. In this study, we investigated the effects of IFN-α2, IFN-β, and the IFN-inducer TAK-981 (a SUMOylation inhibitor) on FcR modulation and functional activation in human monocyte subsets and monocyte-derived DCs (moDCs). Using flow cytometry and imaging techniques, we mapped the expression of activating FcγRs (CD64, CD32A, CD16A) and neonatal FcR (FcRn) under steady-state and stimulated conditions. We found that IFN-I selectively downregulates CD16A expression in classical monocytes while preserving other FcRs, whereas TAK-981 reduces FcRn expression in classical monocytes without affecting CD16A. Additionally, IFN-β and TAK-981 but not IFN-α2, selectively enhanced FcγRI expression in moDC. IFN-β also induced a stronger maturation and functional activation program in monocytes and moDCs compared with IFN-α2, whereas TAK-981 largely reproduced the IFN-β-driven phenotype and secretory profile. Furthermore, we demonstrated that IFN-I signaling alters the spatial distribution of FcRs, with IFN-β and TAK-981 promoting distinct redistribution patterns of FcγRs in monocytes and moDCs. These findings reveal a novel layer of FcR regulation, highlighting that IFN-I and IFN inducers differentially modulate FcR expression, localization, and functional activation in a cell-type- and stimulus-specific manner. Overall, this work provides a framework for understanding how IFN-I-based immunotherapies may influence Fc-mediated immune functions while preserving FcRn-dependent antibody persistence.
ER  -